{"transactions":[{"id":901019,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T00:59:12.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":1580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date."}],"balance_after":1580,"derivative":{"exercise_price":27.16,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":1580},"source":{"system":"sec-edgar","filing":"0001537370-26-000001","document":"form4-02182026_120208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000153737026000001/form4-02182026_120208.xml","form_type":"4"}},{"id":901018,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T00:59:12.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":33989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on February 2, 2026 and each month thereafter, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date."}],"balance_after":33989,"derivative":{"exercise_price":27.16,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":33989},"source":{"system":"sec-edgar","filing":"0001537370-26-000001","document":"form4-02182026_120208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000153737026000001/form4-02182026_120208.xml","form_type":"4"}},{"id":1071139,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-08T16:05:49.000Z","date":"2025-08-08","kind":"other","planned":false,"acquired":false,"shares":3099265,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation (\"Purchaser\") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors and GP VI, disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI or OrbiMed Advisors, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-021337","document":"form4-08082025_080845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000141588925021337/form4-08082025_080845.xml","form_type":"4"}},{"id":1276597,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-10T22:36:29.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":20491,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":20491,"derivative":{"exercise_price":22.47,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":20491},"source":{"system":"sec-edgar","filing":"0001415889-25-003519","document":"form4-02102025_100224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588925003519/form4-02102025_100224.xml","form_type":"4"}},{"id":1462179,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-02T16:45:12.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":12770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement between OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefits thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP."}],"balance_after":12770,"derivative":{"exercise_price":2.69,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":12770},"source":{"system":"sec-edgar","filing":"0001415889-24-018925","document":"form4-07022024_040706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000141588924018925/form4-07022024_040706.xml","form_type":"4"}},{"id":1508990,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T21:03:50.000Z","date":"2024-05-16","kind":"sale","planned":false,"acquired":false,"shares":1000000,"price":22.14,"value":22140000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VII, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7663349,"source":{"system":"sec-edgar","filing":"0000947871-24-000501","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000094787124000501/ownership.xml","form_type":"4"}},{"id":1508989,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T21:03:50.000Z","date":"2024-05-16","kind":"sale","planned":false,"acquired":false,"shares":33300,"price":22.14,"value":737262.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VII, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":254814,"source":{"system":"sec-edgar","filing":"0000947871-24-000501","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000094787124000501/ownership.xml","form_type":"4"}},{"id":1633766,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-21T00:30:01.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":23364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."}],"balance_after":23364,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":23364},"source":{"system":"sec-edgar","filing":"0001415889-24-004488","document":"form4a-02212024_120247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004488/form4a-02212024_120247.xml","form_type":"4/A","original_submission_date":"2024-02-15"}},{"id":1640965,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T01:50:25.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":16835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":16835,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":16835},"source":{"system":"sec-edgar","filing":"0001415889-24-004016","document":"form4-02162024_010218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000141588924004016/form4-02162024_010218.xml","form_type":"4"}},{"id":1758829,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-17T18:40:59.000Z","date":"2023-10-16","kind":"grant","planned":false,"acquired":true,"shares":25540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Thirty three and thirty three one hundreds percent (33.33%) (and thirty three and thirty four one hundreds percent (33.34%) for year three) of the shares subject to the option will vest in three (3) annual installments commencing on the date of the first annual general meeting of stockholders occurring after October 12, 2023, subject to the Reporting Person's continuous service through each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement between OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefits thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP."}],"balance_after":25540,"derivative":{"exercise_price":2.61,"expiration_date":"2033-10-15","underlying":"Common Stock","underlying_shares":25540},"source":{"system":"sec-edgar","filing":"0001209191-23-053004","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000120919123053004/doc4.xml","form_type":"4"}},{"id":1824036,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2023-07-24T16:40:42.000Z","date":"2023-07-20","kind":"exercise","planned":false,"acquired":false,"shares":229158,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":229158},"source":{"system":"sec-edgar","filing":"0000947871-23-000778","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787123000778/ownership.xml","form_type":"4"}},{"id":1824035,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2023-07-24T16:40:42.000Z","date":"2023-07-20","kind":"exercise","planned":false,"acquired":false,"shares":266240,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":266240},"source":{"system":"sec-edgar","filing":"0000947871-23-000778","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787123000778/ownership.xml","form_type":"4"}},{"id":1824034,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2023-07-24T16:40:42.000Z","date":"2023-07-20","kind":"exercise","planned":false,"acquired":false,"shares":1249829,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1249829},"source":{"system":"sec-edgar","filing":"0000947871-23-000778","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787123000778/ownership.xml","form_type":"4"}},{"id":1824033,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2023-07-24T16:40:42.000Z","date":"2023-07-20","kind":"exercise","planned":false,"acquired":false,"shares":937372,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":937372},"source":{"system":"sec-edgar","filing":"0000947871-23-000778","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787123000778/ownership.xml","form_type":"4"}},{"id":1824032,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-24T16:40:42.000Z","date":"2023-07-20","kind":"purchase","planned":false,"acquired":true,"shares":416666,"price":12,"value":4999992.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3099265,"source":{"system":"sec-edgar","filing":"0000947871-23-000778","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787123000778/ownership.xml","form_type":"4"}},{"id":1824031,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-24T16:40:42.000Z","date":"2023-07-20","kind":"exercise","planned":false,"acquired":true,"shares":2682599,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2682599,"source":{"system":"sec-edgar","filing":"0000947871-23-000778","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787123000778/ownership.xml","form_type":"4"}},{"id":1884635,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-05-19T20:12:59.000Z","date":"2023-05-17","kind":"exercise","planned":false,"acquired":false,"shares":2125,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the exercise of stock options granted to David P. Bonita (\"Bonita\") on June 2, 2022. Bonita is a member of OrbiMed Advisors LLC (\"OrbiMed Advisors\") and was a member of Imara Inc.'s (\"Imara\") board of directors. Pursuant to an agreement with OrbiMed Advisors and OrbiMed Capital GP VII LLC (\"GP VII\"), Bonita transferred these stock options to OrbiMed Advisors and GP VII, who in turn ensured that the securities issued under these stock options, or the economic benefits thereof, were provided to OrbiMed Private Investments VII, LP (\"OPI VII\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options vested on November 10, 2022 in connection with the merger of Iguana Merger Sub, Inc., a wholly owned subsidiary of Imara, with and into Enliven Therapeutics, Inc. (\"Enliven\"), with Enliven surviving the merger as a wholly owned subsidiary of Imara."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI VII. GP VII is the general partner of OPI VII and OrbiMed Advisors, a registered investment adviser under the Investment Advisers Act, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":4.28,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0000947871-23-000608","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000094787123000608/ownership.xml","form_type":"4"}},{"id":1884634,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T20:12:59.000Z","date":"2023-05-17","kind":"exercise","planned":false,"acquired":true,"shares":2125,"price":4.28,"value":9095.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the exercise of stock options granted to David P. Bonita (\"Bonita\") on June 2, 2022. Bonita is a member of OrbiMed Advisors LLC (\"OrbiMed Advisors\") and was a member of Imara Inc.'s (\"Imara\") board of directors. Pursuant to an agreement with OrbiMed Advisors and OrbiMed Capital GP VII LLC (\"GP VII\"), Bonita transferred these stock options to OrbiMed Advisors and GP VII, who in turn ensured that the securities issued under these stock options, or the economic benefits thereof, were provided to OrbiMed Private Investments VII, LP (\"OPI VII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI VII. GP VII is the general partner of OPI VII and OrbiMed Advisors, a registered investment adviser under the Investment Advisers Act, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8663349,"source":{"system":"sec-edgar","filing":"0000947871-23-000608","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000094787123000608/ownership.xml","form_type":"4"}},{"id":1893107,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-05-15T18:06:26.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":345313,"price":20,"value":6906260.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC (\"OrbiMed GP\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3777778,"source":{"system":"sec-edgar","filing":"0000947871-23-000585","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787123000585/ownership.xml","form_type":"4"}},{"id":1893106,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-05-15T18:06:26.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":14400,"price":21.96,"value":316224.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC (\"OrbiMed GP\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4123091,"source":{"system":"sec-edgar","filing":"0000947871-23-000585","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787123000585/ownership.xml","form_type":"4"}},{"id":1893105,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-05-15T18:06:26.000Z","date":"2023-05-12","kind":"sale","planned":false,"acquired":false,"shares":43200,"price":21.64,"value":934848.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC (\"OrbiMed GP\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4137491,"source":{"system":"sec-edgar","filing":"0000947871-23-000585","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787123000585/ownership.xml","form_type":"4"}},{"id":1893104,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-05-15T18:06:26.000Z","date":"2023-05-11","kind":"sale","planned":false,"acquired":false,"shares":80000,"price":22.26,"value":1780800.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC (\"OrbiMed GP\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4180691,"source":{"system":"sec-edgar","filing":"0000947871-23-000585","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787123000585/ownership.xml","form_type":"4"}},{"id":1911165,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2023-04-28T16:20:07.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":96000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% on each of July 28, 2023, October 28, 2023, January 28, 2024 and April 28, 2024."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":96000,"derivative":{"exercise_price":2.67,"expiration_date":"2033-04-27","underlying":"Ordinary Shares","underlying_shares":96000},"source":{"system":"sec-edgar","filing":"0001104659-23-053002","document":"tm2314094-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000110465923053002/tm2314094-5_4seq1.xml","form_type":"4"}},{"id":1923778,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-07T00:18:37.000Z","date":"2023-02-23","kind":"grant","planned":false,"acquired":true,"shares":27567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":27567,"derivative":{"exercise_price":25.28,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":27567},"source":{"system":"sec-edgar","filing":"0001209191-23-023665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123023665/doc4.xml","form_type":"4"}},{"id":1990389,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T02:53:13.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":288114,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the \"Merger Agreement\"), by and among Imara Inc. (\"Imara\"), Enliven Therapeutics, Inc., (\"Enliven\") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the \"Merger Sub\"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of  Imara (the \"Merger\"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed \"Enliven Therapeutics, Inc.\" and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol \"ELVN.\""},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."}],"balance_after":288114,"source":{"system":"sec-edgar","filing":"0001209191-23-013517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123013517/doc4.xml","form_type":"4"}},{"id":1990388,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T02:53:13.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":7611458,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the \"Merger Agreement\"), by and among Imara Inc. (\"Imara\"), Enliven Therapeutics, Inc., (\"Enliven\") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the \"Merger Sub\"), which provided for the merger of Merger Sub with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of  Imara (the \"Merger\"). At the effective time of the Merger, each share of Enliven common stock was converted into the right to receive a number of shares of Imara common stock equal to an exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock. After completion of the Merger, the combined company will be renamed \"Enliven Therapeutics, Inc.\" and the common stock of the combined company will trade on The Nasdaq Stock Market under the symbol \"ELVN.\""},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act, is the managing member of GP VII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L.Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7611458,"source":{"system":"sec-edgar","filing":"0001209191-23-013517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919123013517/doc4.xml","form_type":"4"}},{"id":2075963,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-12-27T17:32:02.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":92992,"price":24.11,"value":2242037.12,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the Ordinary Shares sold, ranging from a low of $23.90 to a high of $24.35 per Ordinary Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Ordinary Shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC (\"OrbiMed GP\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":34085528,"source":{"system":"sec-edgar","filing":"0000947871-22-001256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787122001256/ownership.xml","form_type":"4"}},{"id":2075962,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-12-27T17:32:02.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":1116048,"price":23.23,"value":25925795.04,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the Ordinary Shares sold, ranging from a low of $22.89 to a high of $23.88 per Ordinary Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Ordinary Shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC (\"OrbiMed GP\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":34178520,"source":{"system":"sec-edgar","filing":"0000947871-22-001256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787122001256/ownership.xml","form_type":"4"}},{"id":2075961,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-12-27T17:32:02.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":961328,"price":22.27,"value":21408774.56,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the Ordinary Shares sold, ranging from a low of $21.89 to a high of $22.87 per Ordinary Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Ordinary Shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC (\"OrbiMed GP\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":35294568,"source":{"system":"sec-edgar","filing":"0000947871-22-001256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787122001256/ownership.xml","form_type":"4"}},{"id":2075960,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-12-27T17:32:02.000Z","date":"2022-12-22","kind":"sale","acquired":false,"shares":684696,"price":22.07,"value":15111240.72,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the Ordinary Shares sold, ranging from a low of $22.00 to a high of $22.26 per Ordinary Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Ordinary Shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC (\"OrbiMed GP\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":36255896,"source":{"system":"sec-edgar","filing":"0000947871-22-001256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787122001256/ownership.xml","form_type":"4"}},{"id":2075959,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-12-27T17:32:02.000Z","date":"2022-12-22","kind":"sale","acquired":false,"shares":3284800,"price":21.71,"value":71313008.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the Ordinary Shares sold, ranging from a low of $21.00 to a high of $21.99 per Ordinary Share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Ordinary Shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Consists of American Depository Shares (\"ADSs\") held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). Each ADS represents eight Ordinary Shares of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC (\"OrbiMed GP\") is the general partner of OPI VI and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of OrbiMed GP. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":36940592,"source":{"system":"sec-edgar","filing":"0000947871-22-001256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000094787122001256/ownership.xml","form_type":"4"}},{"id":2287661,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2022-04-29T16:45:27.000Z","date":"2022-04-28","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% on each of July 28, 2022, October 28, 2022, January 28, 2023 and April 28, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":200000,"derivative":{"exercise_price":0.5038,"expiration_date":"2032-04-27","underlying":"Ordinary Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-22-053703","document":"tm2214046-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000110465922053703/tm2214046-3_4seq1.xml","form_type":"4"}},{"id":2608155,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":66205,"kind":"person","name":"Gupta Rishi","position":1,"cik":"0001537370","reported_name":"Gupta Rishi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2021-08-10T16:46:43.000Z","date":"2021-08-09","kind":"grant","acquired":true,"shares":64000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% on August 9, 2021, 25% on November 1, 2021, 25% on February 1, 2022 and 25% on May 1, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":64000,"derivative":{"exercise_price":0.775,"expiration_date":"2031-08-08","underlying":"Ordinary Shares","underlying_shares":64000},"source":{"system":"sec-edgar","filing":"0001104659-21-102897","document":"tm2124631-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1537370/000110465921102897/tm2124631-8_4seq1.xml","form_type":"4"}}]}